Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept & continue
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Russia withdraws from key eastern city of Lyman as Ukrainians advance
    • Desperate Russians fleeing Putin’s war draft stream into Kazakhstan
    • A broken insurance market threatens Florida and its star governor
    • Cold weather warning adds to Europe’s gloom as it battles energy crisis
    • Ukrainians vow to push past Lyman as pressure on Putin grows
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Companies
      Sections
      • Companies Home
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
      Most Read
      • Moderna refused China request to reveal vaccine technology
      • Elon Musk unveils Tesla’s humanoid robot prototype
      • UK banks set for bumper profits despite mortgage market freeze
      • Inside the breakdown of the UK’s mortgage machine
      • Prestigious Hong Kong flats stand empty as property market slumps
    • Tech
    • Markets
      Sections
      • Markets Home
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      Most Read
      • Truss says British economy ‘needs a reset’ after market sell-off
      • Seven days that shook the UK
      • Limiting the shock: adjusting personal finances to market turmoil
      • Sterling almost erases losses from Kwasi Kwarteng’s mini-Budget
      • British Steel’s Chinese owner seeks multimillion-pound government rescue package
    • Climate
    • Opinion
      Sections
      • Opinion Home
      • Columnists
      • The FT View
      • The Big Read
      • Lex
      • Obituaries
      • Letters
      Most Read
      • Liz Truss: the normie playing the rebel
      • The complexities of cheating in chess
      • The housing crisis sits at the centre of Britain’s ills 
      • Lasting effects of ‘mini’ Budget will be felt far beyond the trading floors
      • The business card is back, sort of 
    • Work & Careers
      Sections
      • Work & Careers Home
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      Most Read
      • Mars’ outgoing CEO on succession, family businesses and eating his own dog food
      • Carlo Rovelli: ‘Science is not just about writing equations. It’s about reconceptualising the world’
    • Life & Arts
      Sections
      • Life & Arts Home
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
      Most Read
      • Everything must go – Pharrell Williams is selling off his legacy
      • Hong Kong’s expat party continues — but for how long?
      • The art and science of picking winning teams
      • Summer is over. But the UK is unprepared for the heatwaves to come
      • From Mozart to modernism: an architectural adventure in Vienna
    • HTSI
    MenuSearch
    • Home
    • World
    • US
    • Companies
    • Tech
    • Markets
    • Climate
    • Opinion
    • Work & Careers
    • Life & Arts
    • HTSI
    Financial Times
    SubscribeSign In

    Hannah Kuchler

    Global Pharmaceuticals Correspondent
    Hannah Kuchler reports on the pharmaceutical industry and the Covid-19 pandemic. She previously covered US pharma and biotech in New York and the technology industry in Silicon Valley.
    Email Hannah Kuchler @hannahkuchler  on Twitter (link opens in a new browser window)
    Email Hannah Kuchler @hannahkuchler  on Twitter (link opens in a new browser window)

    Add to myFT Digest

    Add this topic to your myFT Digest for news straight to your inbox

    • Sunday, 21 August, 2022
      The Big Read
      Randox: the next test for the UK government’s favourite diagnostics firm

      The company that made hundreds of millions from Covid-19 contracts wants to normalise private health testing

    • Saturday, 20 August, 2022
      Covid-19 vaccines
      GSK vaccine chief aims to break dominance of mRNA shots

      Group developing jab with Sanofi that could have benefits

    • Friday, 19 August, 2022
      News in-depthBiotech
      Revolutionary Crispr gene editing speeds from lab to treatment room

      The first drug to make use of technology discovered only a decade ago will be with regulators by the end of the year

    • Tuesday, 16 August, 2022
      AstraZeneca PLC
      AstraZeneca sues former executive over move to rival GSK

      Pharma group alleges breach of non-compete agreement to delay start date of departing business development official

    • Monday, 15 August, 2022
      Covid-19 vaccines
      UK becomes first country to approve Omicron-specific Covid booster

      Moderna’s two-strain shot will target both the original strain and BA.1 in step with European regulators

    • Sunday, 14 August, 2022
      The Big Read
      How science is getting closer to a world without animal testing

      New technology involving miniature human organs built in a lab is a step towards better treatments and ending a contentious practice

    • Friday, 12 August, 2022
      NHS England
      NHS England to increase beds and call handlers as winter crisis looms

      Push to create equivalent of 7,000 extra beds and boost recruitment follows testing summer for health service

    • Thursday, 11 August, 2022
      Pharmaceuticals sector
      Pharma groups lose £30bn of value on heartburn drug lawsuit worries

      Companies face thousands of pending personal injury cases linking Zantac to cancer

    • Monday, 8 August, 2022
      Covid-19 vaccines
      BioNTech and Pfizer to begin vaccine clinical trial for new Covid variants

      German biotech aims for ‘prolonged and broad protection’ as sales and earnings miss expectations

    • Saturday, 30 July, 2022
      AstraZeneca PLC
      AstraZeneca to double number of countries where US biotech arm sells rare disease drugs

      Anglo-Swedish pharmaceutical group wants to capitalise on its $39bn acquisition of Alexion

    • Friday, 29 July, 2022
      AstraZeneca PLC
      AstraZeneca raises forecasts after strong Covid and cancer drug sales

      Chief executive says revenue rise will allow drugmaker to boost investment in R&D

    • Wednesday, 27 July, 2022
      GSK PLC
      GSK raises profit guidance after strong sales of shingles vaccine

      Quarterly figures beat expectations as pharma group strengthens pipeline of new drugs

    • Thursday, 21 July, 2022
      Joe Biden
      Joe Biden has contracted Covid, White House says

      US president has ‘very mild symptoms’ and is taking Pfizer antiviral pill

    • Wednesday, 20 July, 2022
      Biotech
      Cambridge biotech Abcam to abandon London listing for Nasdaq

      Further blow to UK stock market comes despite government’s efforts to promote life sciences

    • Saturday, 16 July, 2022
      GSK PLC
      GSK split will help deal with ‘perennial underperformance’, says chief

      Emma Walmsley believes listing of consumer health business will strengthen pharma division

    • Thursday, 14 July, 2022
      FT Magazine
      A new ‘miracle’ weight-loss drug really works — raising huge questions

      Novo Nordisk’s Wegovy uses a hormone to regulate hunger. It’s wildly effective, but is it misguided?

    • Thursday, 14 July, 2022
      Health
      UK lags behind EU in authorising new medicines after Brexit

      Experts attribute shortfall to small size of British market now it is regulated separately and complexity of dealing with NHS

    • Wednesday, 13 July, 2022
      Pfizer Inc
      Why Pfizer’s ‘living with Covid’ pill is not a miracle drug

      Antiviral treatment Paxlovid is being widely prescribed despite questions about its effectiveness

    • Sunday, 10 July, 2022
      Covid-19 vaccines
      More than 1bn Covid vaccine jabs wasted in pandemic, data analysis suggests

      Shots unused due to factors including hesitancy, improper storage and donations delivered close to expiry dates

    • Thursday, 7 July, 2022
      Pharmaceuticals sector
      Merck in talks over $40bn deal for cancer biotech SeaGen

      US group attracted by approved drugs as it prepares to lose patent protection of Keytruda

    • Wednesday, 6 July, 2022
      GSK PLC
      GSK investor support for spin-off vindicates rejection of Unilever bid, says chief

      Vote to separate consumer healthcare paves way for London’s largest stock market listing in a decade

    • Wednesday, 6 July, 2022
      Special ReportHealth at Work
      Employers urged to help workers navigate stresses of cost of living crisis

      Mounting money worries spark calls for companies to support workers’ financial wellbeing

    • Tuesday, 5 July, 2022
      CureVac GmbH
      CureVac sues BioNTech over mRNA patents

      Pharma group seeks compensation from Covid vaccine maker for alleged IP infringements

    • Friday, 1 July, 2022
      Covid-19 vaccines
      Oxford BioMedica extends Covid vaccine deal with AstraZeneca

      New three-year contract in place if UK drugmaker continues to manufacture the jab

    • Wednesday, 29 June, 2022
      Q&ACoronavirus pandemic
      How worried should we be about new Covid variants?

      FT science editor Clive Cookson and global pharma correspondent Hannah Kuchler answered your questions about rising Omicron infections and vaccine efficiency

    Previous page You are on page 1 Next page

    Useful links

    Support

    View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

    Legal & Privacy

    Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

    Services

    Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT ChannelsSecondary Schools

    Tools

    PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

    Community & Events

    FT CommunityFT LiveFT ForumsFT Board DirectorBoard Director Programme

    More from the FT Group

    Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2022. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
    The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
    Financial Times

    International Edition

    Subscribe for full access
    • Switch to UK Edition
    • Top sections
    • Home
    • World
      • Global Economy
      • UK
      • US
      • China
      • Africa
      • Asia Pacific
      • Emerging Markets
      • Europe
      • War in Ukraine
      • Americas
      • Middle East & North Africa
      • Australia & NZ
    • US
      • US Economy
      • US Companies
      • US Politics & Policy
    • Companies
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
    • Tech
    • Markets
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
    • Climate
    • Opinion
      • Columnists
      • The FT View
      • The Big Read
      • Lex
      • Obituaries
      • Letters
    • Work & Careers
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
    • Life & Arts
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
    • Personal Finance
      • Property & Mortgages
      • Investments
      • Pensions
      • Tax
      • Banking & Savings
      • Advice & Comment
      • Next Act
    • HTSI
    • Special Reports
    • FT recommends
    • Lex
    • Alphaville
    • Lunch with the FT
    • FT Globetrotter
    • #techAsia
    • Moral Money
    • FTfm
    • Newsletters
    • Video
    • Podcasts
    • News feed
    • FT Community
      • FT Live
      • FT Forums
      • Board Director Programme
    • myFT
    • Portfolio
    • Today's Newspaper (ePaper)
    • Crossword
    • Our Apps
    • Help Centre
    • Subscribe
    • Sign In